Blood Culture Diagnostic Techniques Compared for Human Brucellosis
|
By LabMedica International staff writers Posted on 16 Apr 2014 |

Image: Scanning electron micrograph of Brucella abortus (Photo courtesy of the Czech University of Life Science).
Isolation of the bacteria Brucella is the gold standard in the laboratory diagnosis of brucellosis and as the organism is intracellular, the number of circulating bacteria is usually low.
Three different blood culture methods, the lysis concentration (LC), clot culture and conventional Castaneda blood culture techniques, have been compared for the isolation rate and recovery time in the diagnosis of human brucellosis.
Microbiologists at the Shri B. M. Patil Medical College (Bijapur, Karnataka, India) performed blood cultures by LC, clot culture and conventional method in 169 patients who had antibody titers equal to or greater than 160 international units by the serum agglutination test (SAT).
For the conventional culture technique, the blood specimen was inoculated aseptically into the broth phase of Castaneda's biphasic medium consisting of brain heart infusion agar and broth with Brucella selective supplement (Hi-Media; Mumbai, India). For the LC technique, the mixtures centrifuged and the supernatant was discarded and the sediment was inoculated in the Castaneda's medium, instead of culture plate.
For the clot culture technique, the blood clot was preserved in the sterile screw capped plastic tube with glass beads after removal of serum was used for this method. The clot was disrupted by shaking the tubes on a shaker for 15 minutes and the disrupted clot was then inoculated in Castaneda's medium. The media were incubated at 37 °C with 10% carbon dioxide for a maximum of 30 days. Provisional confirmation and biotyping of the isolate was done by performing slide agglutination test using B. abortus and B. melitensis monospecific antisera (Murex Biotech; Dartford, UK).
Overall blood culture positivity was found to be 24.8% by conventional culture, 34.9% by clot method, and 43.1% by the lysis technique. The mean recovery time by lysis and clot culture techniques was significantly less than conventional method, resulting in an overall difference of nearly six and four days respectively.
The authors concluded that for the isolation of Brucella from blood specimen, LC method is better than conventional Castaneda's method as the isolation rate is high and the recovery time is less. Clot culture is a better option when a second blood sample cannot be obtained for culture. As lysis and clot culture techniques are sensitive, simple and inexpensive and yield earlier results, they can be adapted in the technically and economically deprived areas where automated systems are not feasible. The study was published on March 19, 2014, in the Journal of Laboratory Physicians.
Related Links:
Shri B. M. Patil Medical College
Hi-Media
Murex Biotech
Three different blood culture methods, the lysis concentration (LC), clot culture and conventional Castaneda blood culture techniques, have been compared for the isolation rate and recovery time in the diagnosis of human brucellosis.
Microbiologists at the Shri B. M. Patil Medical College (Bijapur, Karnataka, India) performed blood cultures by LC, clot culture and conventional method in 169 patients who had antibody titers equal to or greater than 160 international units by the serum agglutination test (SAT).
For the conventional culture technique, the blood specimen was inoculated aseptically into the broth phase of Castaneda's biphasic medium consisting of brain heart infusion agar and broth with Brucella selective supplement (Hi-Media; Mumbai, India). For the LC technique, the mixtures centrifuged and the supernatant was discarded and the sediment was inoculated in the Castaneda's medium, instead of culture plate.
For the clot culture technique, the blood clot was preserved in the sterile screw capped plastic tube with glass beads after removal of serum was used for this method. The clot was disrupted by shaking the tubes on a shaker for 15 minutes and the disrupted clot was then inoculated in Castaneda's medium. The media were incubated at 37 °C with 10% carbon dioxide for a maximum of 30 days. Provisional confirmation and biotyping of the isolate was done by performing slide agglutination test using B. abortus and B. melitensis monospecific antisera (Murex Biotech; Dartford, UK).
Overall blood culture positivity was found to be 24.8% by conventional culture, 34.9% by clot method, and 43.1% by the lysis technique. The mean recovery time by lysis and clot culture techniques was significantly less than conventional method, resulting in an overall difference of nearly six and four days respectively.
The authors concluded that for the isolation of Brucella from blood specimen, LC method is better than conventional Castaneda's method as the isolation rate is high and the recovery time is less. Clot culture is a better option when a second blood sample cannot be obtained for culture. As lysis and clot culture techniques are sensitive, simple and inexpensive and yield earlier results, they can be adapted in the technically and economically deprived areas where automated systems are not feasible. The study was published on March 19, 2014, in the Journal of Laboratory Physicians.
Related Links:
Shri B. M. Patil Medical College
Hi-Media
Murex Biotech
Latest Microbiology News
- Breath Analysis Approach Offers Rapid Detection of Bacterial Infection
- Study Highlights Accuracy Gaps in Consumer Gut Microbiome Kits
- WHO Recommends Near POC Tests, Tongue Swabs and Sputum Pooling for TB Diagnosis
- New Imaging Approach Could Help Predict Dangerous Gut Infection
- Rapid Sequencing Could Transform Tuberculosis Care
- Blood-Based Viral Signature Identified in Crohn’s Disease
- Hidden Gut Viruses Linked to Colorectal Cancer Risk
- Three-Test Panel Launched for Detection of Liver Fluke Infections
- Rapid Test Promises Faster Answers for Drug-Resistant Infections
- CRISPR-Based Technology Neutralizes Antibiotic-Resistant Bacteria
- Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease
- AI-Powered Platform Enables Rapid Detection of Drug-Resistant C. Auris Pathogens
- New Test Measures How Effectively Antibiotics Kill Bacteria
- New Antimicrobial Stewardship Standards for TB Care to Optimize Diagnostics
- New UTI Diagnosis Method Delivers Antibiotic Resistance Results 24 Hours Earlier
- Breakthroughs in Microbial Analysis to Enhance Disease Prediction
Channels
Clinical Chemistry
view channel
Blood-Based Screening Test Targets Early Detection of Colorectal Cancer
Colorectal cancer (CRC) is a leading cause of cancer-related death worldwide, with more than 60% of cases still diagnosed at a late stage. Uptake of existing screening tools remains suboptimal,... Read more
Automated NfL Assay Supports Monitoring of Neurological Disorders
Neuroaxonal injury occurs across a wide range of neurological disorders and remains difficult to monitor noninvasively over time. Blood-based measurement of neurofilament light chain (NfL) provides a biologically... Read moreMolecular Diagnostics
view channel
New Respiratory Panel Expands Pathogen Detection to 25 Targets
Respiratory infections often present with overlapping symptoms, complicating differential diagnosis in acute and community settings. The stakes are higher for older adults, young children, and people with... Read more
Simple Nasal Swab May Reveal Early Signs of Alzheimer’s Disease
Alzheimer’s disease affects millions worldwide but remains difficult to detect at its earliest, pre-symptomatic stage. Clinicians need tools that can identify biological changes before cognitive symptoms... Read moreHematology
view channel
Rapid Cartridge-Based Test Aims to Expand Access to Hemoglobin Disorder Diagnosis
Sickle cell disease and beta thalassemia are hemoglobin disorders that often require referral to specialized laboratories for definitive diagnosis, delaying results for patients and clinicians.... Read more
New Guidelines Aim to Improve AL Amyloidosis Diagnosis
Light chain (AL) amyloidosis is a rare, life-threatening bone marrow disorder in which abnormal amyloid proteins accumulate in organs. Approximately 3,260 people in the United States are diagnosed... Read moreImmunology
view channel
Study Identifies Inflammatory Pathway Driving Immunotherapy Resistance in Bladder Cancer
Bladder cancer remains a prevalent malignancy with variable responses to immune checkpoint inhibitors. Clinicians often observe elevated C-reactive protein and interleukin-6 in affected patients, yet the... Read more
Microfluidic Chip Detects Cancer Recurrence from Immune Response Signals
Early identification of treatment response and relapse remains a major challenge in solid tumors, where minimal residual disease is difficult to detect with routine imaging and blood tests.... Read morePathology
view channel
Biopsy-Based Gene Test Predicts Recurrence Risk in Lung Adenocarcinoma
Lung cancer is the leading cause of cancer death, killing more people in the United States than breast, prostate, and colon cancers combined. In lung adenocarcinoma (LUAD), tumors that invade nearby blood... Read more
AI-Powered Tool to Transform Dermatopathology Workflow
Skin cancer accounts for the largest number of cancer diagnoses in the United States, placing sustained pressure on pathology services. Diagnostic interpretation can be variable for challenging melanocytic... Read moreTechnology
view channel
Online Tool Supports Family Screening for Inherited Cancer Risk
Genetic test results in oncology often have implications for relatives who may share inherited cancer risk. Many health systems lack structured processes to help patients alert family members, limiting... Read more
Portable Breath Sensor Detects Pneumonia Biomarkers in Minutes
Pneumonia is commonly confirmed with chest X-rays or laboratory assays that can take hours, delaying clinical decisions in acute and outpatient settings. Breath-based diagnostics promise faster answers... Read moreIndustry
view channel
Integrated DNA Technologies Expands into Clinical Diagnostics
Integrated DNA Technologies (IDT; Coralville, Iowa, USA) has announced the launch of Archer FUSIONPlex-HT Dx and VARIANTPlex-HT Dx. This launch marks the company’s first in vitro diagnostic (IVD) offerings... Read more








